Drug Profile
Odetiglucan - HiberCell
Alternative Names: B-glucan PGG; BTH-1677; Imprime; Imprime PGG; Soluble beta glucan - HiberCellLatest Information Update: 05 Jul 2023
Price :
$50
*
At a glance
- Originator Biothera
- Developer Biothera; Dana-Farber Cancer Institute; HiberCell; Mayo Clinic; Merck Sharp & Dohme
- Class Antibacterials; Antineoplastics; Beta Glucans
- Mechanism of Action Antibody-dependent cell cytotoxicity; Dectin 1 stimulants; Fc gamma receptor IIA modulators; Immunostimulants; Macrophage 1 antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Non-Hodgkin's lymphoma; Non-small cell lung cancer; Triple negative breast cancer
- Phase I Adenocarcinoma; Liver metastases
- Suspended Infections
- No development reported Follicular lymphoma
- Discontinued Chronic lymphocytic leukaemia; Colorectal cancer; Head and neck cancer; Malignant melanoma; Myelosuppression; Stem cell mobilisation
Most Recent Events
- 12 Apr 2023 HiberCell in collaboration with Merck completes a phase II trial in Breast cancer (Combination therapy, Second line therapy or greater, Late-stage study, Metastatic disease) in USA (NCT05159778)
- 08 Feb 2023 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia (Combination therapy, First-line therapy) in USA (IV)
- 08 Feb 2023 Discontinued - Phase-II for Head and neck cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)